Psychedelics get a boost from the White House

VideoSTATus Report Psychedelics get a boost from the White House In this week’s STATus Report, Alex Hogan chats with Washington correspondent Daniel Payne Manage alerts for this article Email this article Share this article By Alex HoganApril 24, 2026 Senior Multimedia Producer Alex Hogan[email protected]Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. President Trump recently signed an executive order which aims to increase access to psychedelic drug treatments.

He was joined at the signing by podcaster Joe Rogan, who said he’ ha’d messaged the president about research on the psychedelic ibogaine. In this week’s STATus Report, host Alex Hogan chats with STAT Washington correspondent Daniel Payne about what the executive order does and doesn’t do. Hogan also looks at why ibogaine, and psychedelic drugs more broadly, are increasingly being taken seriously for stubbornly hard-to-treat conditions like addiction, depression, and PTSD.Advertisement Mental Health, Pharmaceuticals, Policy, psychedelics, public health Submit a correction requestReprints Alex Hogan Senior Multimedia Producer Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series.

You can follow him on Bluesky. Newsletter The latest updates in federal health agencies, research institutes, and U.S. policy Recommended STATus Report April 10, 2026 How sports betting apps hook users STATus Report April 2, 2026 STAT reporter goes up against radiologists to spot deepfake X-rays Advertisement STATus Report March 26, 2026 Health influencers talk social media and mental health STATus Report March 13, 2026 How STAT would cover ‘The Fugitive’ if its pharma scandal were real STATus Report March 6, 2026 How the ‘holy grail’ weight loss pill became a reality, and what comes next Subscriber Picks